Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Debt (2021 - 2024)

Inmune Bio's Total Debt history spans 4 years, with the latest figure at $5.0 million for Q3 2024.

  • For Q3 2024, Total Debt fell 59.65% year-over-year to $5.0 million; the TTM value through Sep 2024 reached $5.0 million, down 59.65%, while the annual FY2023 figure was $9.9 million, 32.5% down from the prior year.
  • Total Debt for Q3 2024 was $5.0 million at Inmune Bio, down from $10.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $15.0 million in Q1 2024 and bottomed at $4.8 million in Q2 2023.
  • The 4-year median for Total Debt is $14.4 million (2021), against an average of $12.4 million.
  • The largest annual shift saw Total Debt tumbled 66.91% in 2023 before it surged 106.95% in 2024.
  • A 4-year view of Total Debt shows it stood at $14.5 million in 2021, then rose by 1.65% to $14.7 million in 2022, then tumbled by 32.5% to $9.9 million in 2023, then crashed by 49.66% to $5.0 million in 2024.
  • Per Business Quant, the three most recent readings for INMB's Total Debt are $5.0 million (Q3 2024), $10.0 million (Q2 2024), and $15.0 million (Q1 2024).